National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

bevacizumabPatient Information
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:anti-VEGF humanized monoclonal antibody
anti-VEGF monoclonal antibody
anti-VEGF rhuMAb
recombinant humanized anti-VEGF monoclonal antibody
rhuMAb VEGF
US brand name:Avastin
Abbreviation:rhuMab-VEGF



Previous:Betadine, BetaMarc, betamethasone, Betaseron, betulinic acid
Next:bexarotene, Bextra, Bexxar, BI 2536, Biaxin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov